Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Jun;22(6):734-40.
doi: 10.18553/jmcp.2016.15248. Epub 2016 Apr 28.

Medication Reconciliation in Oncological Patients: A Randomized Clinical Trial

Triana González-Carrascosa Vega  1 , Jesús Francisco Sierra-Sánchez  2 , María José Martínez-Bautista  3 , Fátima García-Martín  3 , Francisco Suárez-Carrascosa  3 , Jose Manuel Baena-Cañada  4
Affiliations
Randomized Controlled Trial

Medication Reconciliation in Oncological Patients: A Randomized Clinical Trial

Triana González-Carrascosa Vega et al. J Manag Care Spec Pharm. 2016 Jun.

Abstract

Background: Medication reconciliation is considered to be an important strategy for increasing the safety of medication use. However, few studies have been carried out showing the effect of a medication reconciliation program on the incidence of reconciliation errors (REs) in oncological patients treated in the outpatient setting.

Objective: To measure the effect of a medication reconciliation program on the incidence of reconciliation error that reached the patient (RERP) in cancer patients receiving chemotherapy as outpatients.

Methods: A randomized, prospective, controlled study was carried out to identify the proportion of patients with at least 1 RERP. Medication reconciliation (intervention group) was compared with standard practice (control group) in patients starting new chemotherapy and who were receiving at least 1 home medication before the start of chemotherapy. A prespecified analysis of factors capable of influencing the occurrence of RE in oncological patients was also carried out.

Results: A total of 147 patients were included (76 in the intervention group and 71 controls) in this study. There were 3 (4%) patients with RERP (primary endpoint) in the intervention group and 21 (30%) patients in the control group (relative risk [RR] = 0.13, 95% CI = 0.04-0.43; P = 0.0009). The prespecified analysis of the effects of the Eastern Cooperative Oncology Group performance status (ECOG), Charlson Comorbidity Index score, and degree of poly-medication upon the number of patients with RE showed the Charlson Comorbidity Index to be unrelated to RE occurrence. However, the risk of RE was greater in patients with ECOG ≥ 2 (RR = 2.18, 95% CI = 1.4-3.4; P = 0.018) and among patients with major poly-medication (RR = 2.49, 95% CI = 1.52-4.09; P <0.001).

Conclusions: Medication reconciliation results in a marked decrease in RERP in cancer patients. The factors that may influence RE occurrence in oncological patients have not been fully established, although parameters such as the degree of poly-medication and performance status may play a role.

Disclosures: No outside funding supported this study. The authors declare that they have no affiliations with or financial interests in any company, product, or service described in the manuscript. Study concept and design were contributed by Sierra-Sánchez, Martínez-Bautista, Baena-Cañada, and González-Carrascosa Vega. Martínez-Bautista, García-Martín, Suárez-Carrascosa, and González-Carrascosa Vega collected the data, which was interpreted by Sierra-Sánchez, Martínez-Bautista, Baena-Cañada, and González-Carrascosa Vega. The manuscript was written by Sierra-Sánchez and González-Carrascosa Vega and revised by Sierra-Sánchez, Martínez-Bautista, Baena-Cañada, and González-Carrascosa Vega.

PubMed Disclaimer

Conflict of interest statement

No outside funding supported this study. The authors declare that they have no affiliations with or financial interests in any company, product, or service described in the manuscript.

Study concept and design were contributed by Sierra-Sánchez, Martínez-Bautista, Baena-Cañada, and González-Carrascosa Vega. Martínez-Bautista, García-Martín, Suárez-Carrascosa, and González-Carrascosa Vega collected the data, which was interpreted by Sierra-Sánchez, Martínez-Bautista, Baena-Cañada, and González-Carrascosa Vega. The manuscript was written by Sierra-Sánchez and González-Carrascosa Vega and revised by Sierra-Sánchez, Martínez-Bautista, Baena-Cañada, and González-Carrascosa Vega.

Figures

FIGURE 1
FIGURE 1
Timeline of Study Procedures
FIGURE 2
FIGURE 2
Participant Screening Flowchart
See this image and copyright information in PMC

References

    1. Joint Commission Accreditation Healthcare Organizations.. Comprehensive Accreditation Manual for Hospitals (CAMH): The Official Handbook. Oakbrook Terrace, IL: Joint Commission Resources, 2006.
    1. Institute for Healthcare Improvement.. How-to guide: prevent adverse drug events (medication reconciliation). Revised March 2016. Available at: http://www.ihi.org/resources/Pages/Tools/HowtoGuidePreventAdverseDrugEve.... Accessed April 3, 2016.
    1. Gleason KM, Brake H, Agramonte V, Perfetti C.. Medications at transitions and clinical handoffs (MATCH) toolkit for medication reconciliation. (Prepared by the Island Peer Review Organization, Inc., under Contract No. HHSA2902009000 13C). AHRQ Publication No. 11(12)-0059. Rockville, MD: Agency for Healthcare Research and Quality. Revised August 2012. Available at: http://www.ahrq.gov/sites/default/files/publications/files/match.pdf. Accessed March 18, 2016.
    1. Alfaro-Lara ER, Vega-Coca MD, Galván-Banqueri M, et al. .. [Pharmacological treatment conciliation methodology in patients with multiple conditions]. Aten Primaria. 2014;46(2):89-99. [Article in Spanish] - PMC - PubMed
    1. Gleason KM, McDaniel MR, Feinglass J, et al. .. Results of the Medications at Transitions and Clinical Handoffs (MATCH) study: an analysis of medication reconciliation errors and risk factors at hospital admission. J Gen Intern Med. 2010;25(5):441-47. - PMC - PubMed

Publication types

Substances

LinkOut - more resources